Characterization of antibody reactivity to human T-cell lymphotropic virus Types I and II using immunoblot and radioimmunoprecipitation assays

T. M. Hartley, R. F. Khabbaz, R. O. Cannon, J. E. Kaplan, Michael Dale Lairmore

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We have characterized the immunoreactivity to human T-cell lymphotropic virus type I (HTLV-I) among 26,983 persons of various seroprevalence groups by using enzyme immunoassay, immunoblot (IB), and radioimmunoprecipitation assays (RIPA) in accordance with Public Health Service recommended guidelines for the interpretation of serologic test results for HTLV-I infection. IB-indeterminate serum specimens (n = 178) were reactive to HTLV-I gag proteins, and no serum contained only env reactivity. Overall, RIPA resolved 40% of IB-indeterminate serum samples; however, the probability that RIPA would confirm IB-indeterminate samples depended on the seroprevalence of the population tested. HTLV-I gag p19-only reactivity on IB was not a reliable marker of HTLV-I infection, while gag p24 reactivity on IB was clearly associated with positive seroreactive specimens. IB and RIPA tests did not clearly distinguish between HTLV-I and HTLV-II seroreactivities. These data emphasize that patterns of immunoreactivity to HTLV-I antigens are dependent upon the seroprevalence of the risk groups tested. In addition, RIPA detected antibodies to env proteins present in low titer in a substantial number of IB gag-only reactive sera and resolved the HTLV-I antibody status of these sera.

Original languageEnglish (US)
Pages (from-to)646-650
Number of pages5
JournalJournal of Clinical Microbiology
Volume28
Issue number4
StatePublished - 1990
Externally publishedYes

Fingerprint

Radioimmunoprecipitation Assay
Viruses
T-Lymphocytes
Antibodies
Seroepidemiologic Studies
Serum
Virus Diseases
Human T-lymphotropic virus 2
env Gene Products
gag Gene Products
United States Public Health Service
Serologic Tests
Immunoenzyme Techniques
Guidelines

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

Cite this

Characterization of antibody reactivity to human T-cell lymphotropic virus Types I and II using immunoblot and radioimmunoprecipitation assays. / Hartley, T. M.; Khabbaz, R. F.; Cannon, R. O.; Kaplan, J. E.; Lairmore, Michael Dale.

In: Journal of Clinical Microbiology, Vol. 28, No. 4, 1990, p. 646-650.

Research output: Contribution to journalArticle

@article{deae4c37b3b043cba0c3c720c64fc3fd,
title = "Characterization of antibody reactivity to human T-cell lymphotropic virus Types I and II using immunoblot and radioimmunoprecipitation assays",
abstract = "We have characterized the immunoreactivity to human T-cell lymphotropic virus type I (HTLV-I) among 26,983 persons of various seroprevalence groups by using enzyme immunoassay, immunoblot (IB), and radioimmunoprecipitation assays (RIPA) in accordance with Public Health Service recommended guidelines for the interpretation of serologic test results for HTLV-I infection. IB-indeterminate serum specimens (n = 178) were reactive to HTLV-I gag proteins, and no serum contained only env reactivity. Overall, RIPA resolved 40{\%} of IB-indeterminate serum samples; however, the probability that RIPA would confirm IB-indeterminate samples depended on the seroprevalence of the population tested. HTLV-I gag p19-only reactivity on IB was not a reliable marker of HTLV-I infection, while gag p24 reactivity on IB was clearly associated with positive seroreactive specimens. IB and RIPA tests did not clearly distinguish between HTLV-I and HTLV-II seroreactivities. These data emphasize that patterns of immunoreactivity to HTLV-I antigens are dependent upon the seroprevalence of the risk groups tested. In addition, RIPA detected antibodies to env proteins present in low titer in a substantial number of IB gag-only reactive sera and resolved the HTLV-I antibody status of these sera.",
author = "Hartley, {T. M.} and Khabbaz, {R. F.} and Cannon, {R. O.} and Kaplan, {J. E.} and Lairmore, {Michael Dale}",
year = "1990",
language = "English (US)",
volume = "28",
pages = "646--650",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "4",

}

TY - JOUR

T1 - Characterization of antibody reactivity to human T-cell lymphotropic virus Types I and II using immunoblot and radioimmunoprecipitation assays

AU - Hartley, T. M.

AU - Khabbaz, R. F.

AU - Cannon, R. O.

AU - Kaplan, J. E.

AU - Lairmore, Michael Dale

PY - 1990

Y1 - 1990

N2 - We have characterized the immunoreactivity to human T-cell lymphotropic virus type I (HTLV-I) among 26,983 persons of various seroprevalence groups by using enzyme immunoassay, immunoblot (IB), and radioimmunoprecipitation assays (RIPA) in accordance with Public Health Service recommended guidelines for the interpretation of serologic test results for HTLV-I infection. IB-indeterminate serum specimens (n = 178) were reactive to HTLV-I gag proteins, and no serum contained only env reactivity. Overall, RIPA resolved 40% of IB-indeterminate serum samples; however, the probability that RIPA would confirm IB-indeterminate samples depended on the seroprevalence of the population tested. HTLV-I gag p19-only reactivity on IB was not a reliable marker of HTLV-I infection, while gag p24 reactivity on IB was clearly associated with positive seroreactive specimens. IB and RIPA tests did not clearly distinguish between HTLV-I and HTLV-II seroreactivities. These data emphasize that patterns of immunoreactivity to HTLV-I antigens are dependent upon the seroprevalence of the risk groups tested. In addition, RIPA detected antibodies to env proteins present in low titer in a substantial number of IB gag-only reactive sera and resolved the HTLV-I antibody status of these sera.

AB - We have characterized the immunoreactivity to human T-cell lymphotropic virus type I (HTLV-I) among 26,983 persons of various seroprevalence groups by using enzyme immunoassay, immunoblot (IB), and radioimmunoprecipitation assays (RIPA) in accordance with Public Health Service recommended guidelines for the interpretation of serologic test results for HTLV-I infection. IB-indeterminate serum specimens (n = 178) were reactive to HTLV-I gag proteins, and no serum contained only env reactivity. Overall, RIPA resolved 40% of IB-indeterminate serum samples; however, the probability that RIPA would confirm IB-indeterminate samples depended on the seroprevalence of the population tested. HTLV-I gag p19-only reactivity on IB was not a reliable marker of HTLV-I infection, while gag p24 reactivity on IB was clearly associated with positive seroreactive specimens. IB and RIPA tests did not clearly distinguish between HTLV-I and HTLV-II seroreactivities. These data emphasize that patterns of immunoreactivity to HTLV-I antigens are dependent upon the seroprevalence of the risk groups tested. In addition, RIPA detected antibodies to env proteins present in low titer in a substantial number of IB gag-only reactive sera and resolved the HTLV-I antibody status of these sera.

UR - http://www.scopus.com/inward/record.url?scp=0025348286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025348286&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 646

EP - 650

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 4

ER -